Search

Our Company
Our Focus
- Therapeutic Areas
- Cardiovascular, Metabolism & Retina
- Immunology
- Infectious Diseases & Vaccines
- Neuroscience
- Oncology
- Pulmonary Hypertension
- Patient Engagement
Our Science

Careers

We’re always seeking talented people who share our vision. Click here to explore opportunities in a variety of disciplines across the globe.
See More >

Leadership Blogs

Get to know our leaders. Read their unique perspectives on how they are working to change the trajectory of health.
See More >

Generation Care™

We’re committed to showing the heart of the caregiver’s experience and providing the kind of support and information that will make a difference.
See More >

Patient Engagement

Janssen partners directly with patients and caregivers as we develop medicines, improve clinical trials, and create educational materials and support programs.
See More >

Research & Development

Our research pipeline is rich with transformational science reflecting our unique approach to innovation.
See More >

R&D Data Science

Using data science and digital health to reimagine the discovery and development of medicines to advance our mission of bringing transformative therapies to patients.
See More >

Collaborating in more than 150 markets.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.

Global

Janssen Global

English | Español
Français | Português (BR)
Italiano | 한국어
РУССКИЙ

Asia Pacific

Asia Pacific (Regional)

English
Australia

English
China

中文
Hong Kong SAR, China

English | 中文
India

English
Japan

日本
Korea

한국어
New Zealand

English

Europe, Middle East & Africa (EMEA)

EMEA (Regional)

English
Austria

Deutsch
Belgium

English | Français | Nederlands
Bulgaria

Български
Croatia

HRVATSKI
Czech Republic

Čeština
Denmark

Dansk
Estonia

English
Finland

Suomi
France

Français
Germany

Deutsch

Greece

ΕΛΛΗΝΙΚΑ
Hungary

Magyar
Ireland

English
Israel

עברית
Italy

Italiano
Latvia

English
Lithuania

English
Netherlands

Nederlands
Norway

Norsk
Poland

Polski

Portugal

Português
Romania

Română
Russia

Русский
Serbia

SRPSKI
Slovakia

SLOVENČINA
Slovenia

Slovenščina
South Africa

English
Spain

Español
Sweden

Svensk
Switzerland

Deutsch | Français
Turkey

Türkçe
United Kingdom

English

Latin America

Latin America (Regional)

ESPAÑOL
Argentina

Español
Bolivia

Español
Brazil

Português
Central America and the Caribbean

Spanish | English
Chile

Español
Colombia

Español
Ecuador

Español
Mexico

Español
Paraguay

Español
Peru

Español
Uruguay

Español

North America

Canada

English | Français
United States

English

Home › ESMO 2021

ESMO 2021

ESMO 2021
Janssen Oncology Virtual Newsroom

Thank you for your interest in spreading the word about Janssen.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Recipient Name *

Recipient Email *

Your Name *

You are going to email the following
Message Subject
An article you might be interested

Message Body
(Your name) thought you would like to see this page[ ] from the Janssen website.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 1 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

LATEST NEWS

RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA® (erdafitinib) in Combination with PD-1 Inhibitor Cetrelimab

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Johnson & Johnson Innovative Medicine